[Durvalumab (malignant biliary tract cancer [BTC]) – Addendum to Commission A23-26]

Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018005251
Original Title: Durvalumab (biliäres Karzinom) - Addendum zum Projekt A23-26
Project Status: Completed
Year Published: 2023
English language abstract: There is no English language summary available
Publication Type: Full HTA
Country: Germany
MeSH Terms
  • Biliary Tract Neoplasms
  • Antibodies, Monoclonal
  • Antineoplastic Agents, Immunological
  • Bile Duct Neoplasms
  • Durvalumab
  • Gemcitabine
  • Cisplatin
  • Biliary Tract Neoplasms
  • Benefit Assessment
  • NCT03875235
Organisation Name: Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address: IQWiG, Im Mediapark, 8, DE-50670 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email: berichte@iqwig.de
Copyright: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.